Hepatogenic diabetes - Current concepts of its pathology and treatment;Der hepatogene diabetes - Aktuelle konzepte zu pathophysiologie und therapie

Deutsche Medizinische Wochenschrift

Volumn 124, Issue 50, 1999, Pages 1530-1535

  Siegel, E G ^a   Gallwitz, B ^b   Schmidt, W E ^b   Folsch U R ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLUCOSE; INSULIN RECEPTOR;

DIABETES MELLITUS; DIABETOGENESIS; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LIVER DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REVIEW;

EID: 0033579373     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1023909     Document Type: Review

References (51)

1. 1 Andus, T., J. Bauer, W. Gerok: Effects of cytokines on the liver. Hepatology 13 (1991), 364-375.
2. 2 Baumann, M., H. Hartmann, C. F. Deacon et al.: Hypersecretion of proinsulin does not explain the hyperinsulinemia of patients with liver cirrhosis. Clin. Endocrinol. 25 (1986), 351-361.
3. 3 Bathena, S. J., N. R. Voyles, S. Smith: Decreased glucagon receptors in diabetic rat hepatocytes.J. clin. Invest. 61 (1978), 1488-1497.
4. 4 Beck, P., D. S. Schaich, M. L. Parker: Correlative studies of growth hormone and insulin plasma concentration with metabolic abnormalities in acromegaly.J. Lab. clin. Med. 66 (1966), 366-379.
5. 5 Blum, W. F.: Insulin-like Growth Factors and their binding proteins. In: Ranke, M. B. (ed): Functional endocrinological diagnostic in children and adolescents. (J+J, Mannheim, 1992), pp. 102-117.
6. 6 Bosch, J., R. Gomis, D. Kravetz, R. Casamitjana, J. Teres, F. Rivera, J. Rodes: Role of spontaneous portal-systemic shunting in hyperinsulinism of cirrhosis. Amer.J. Physiol. 247 (1984), G206-212.
7. 7 Bratusch-Marrain, P., D. Smith, R. A. DeFronzo: The effect of growth hormone on glucose metabolism and insulin secretion in man.J. Clin. Endocrinol. Metab. 55 (1982), 973-982.
8. 8 Caro, J. F.: Insulin resistance in obese and nonobese man.J. clin. Endocrinol. 73 (1991), 691-695.
9. 9 Chupin, M., B. Charbonnel, L. LeBodic, J. Y. Grolleau, F. Chupin, J. Guillon: Glucose tolerance in viral hepatitis. Diabetes 27 (1978), 666-669.
10. 10 Conn, H. O., W. H. Daughaday: Cirrhosis and diabetes.J. Lab. clin. Med. 76 (1970), 678-688.
11. 11 Creutzfeldt, W., K. Sickinger, H. Frerichs: Diabetes bei Lebererkrankungen. In: Pfeiffer, E. F., Hrsg. Handbuch des Diabetes mellitus (Lehmann:München, 1971), 807-859.
12. 12 Creutzfeldt, W., H. Hartmann, M. Nauck, F. Stöckmann: Liver disease and glucose homeostasis. In: Blanchi, L.; W. Gerok; L. Landmann; K. Sickinger; G. A. Stalder (eds). Liver in metabolic diseases. (MTP -Press), Boston, 1983 ), 221-234.
13. 13 Creutzfeldt, W., R. Ebert: New developments in the incretin concept. Diabetologia 28 (1985), 565.
14. 14 Greco, A. V., L. Altomonte, G. Ghirlanda: Somatostatin infusion in liver cirrhosis. Diabetologia 18 (1980), 187-191.
15. 15 Greco, A. V., A. Bertoh, G. Ghirlanda, et al: Insulin resistance in liver cirrhosis. Hormon. metab. Res. 12 (1980), 577-581.
16. 16 Greco, A. V., A. Bertoh, 5. Caputo et al.: Decreased insulin binding to red blood cells in liver cirrhosis. Acta. diabetol. Lat. 20 ( 1983), 251.
17. 17 Hatton, N., H. Kurahachi, K. Ikekubo et al.: Serum growth hormone-binding protein, insulin-like growth factor 1, and growth hormone in patients with liver cirrhosis. Metabolism 41 (1992), 377-381.
18. 18 Hotamisligil, G. S., N. S. Shargill, B.M. Spiegelman: Adipose expression of tumor necrosis factor-alpha. Science 259 (1993), 87-91.
19. 19 Johnston, D. G., K. G. M. M. Alberti, C. Binder: Hormonal and metabole changes in hepatic cirrhosis. Horm. metabol. Res. 14 (1982), 34-39.
20. 20 Krauns, P., W. Ruge: Plasmakatecholaminspiegel bei Lebererkrankungen. Z. Gastroenterol. 23 (1985), 64-73.
21. 21 Kruszynska, Y.T., N. Williams, M. Perry, P. Home: The relationship betweeen insulin sensitivity and skeletal muscle enzyme activities in liver cirrhosis. Hepatology 8 (1988), 1615-1619.
22. 22 Kruszynska, Y. T.: Glucose control in liver disease. Current med. Lit. Gastroenterol. 11 (1992), 9-11.
23. 23 Kruszynska, Y. T., S. Goulas, S. Wollen, N. McIntyre: Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients.J. Hepatol. 28 (1998), 280-291.
24. 24 Memon, R. A., K. R. Feingold, A. H. Moser, W. Doerrler, S. Adi, C. A. Dinarello, C. Grunfeld: Differential effects of interleukin-1 and tumor necrosis factor on ketogenesis. Amer.J. Physiol. 263 (1992), E301-309.
25. 25 Merli, M., F. Leonett, O. Riggio, A. Giaccari, A. Romiti, P. Sbraccia, G. Gamburrano: Resistance to insulin suppression of plasma free fatty acids in liver cirrhosis.J. endocrinol. Invest. 113 (1990), 787-795.
26. 4-induced cirrhosis of rats. Gastroenterology 102 (1992), 223-229.
27. 27 Möller, S., U. Becker: Insulin-like growth factor 1 and growth hormone in chronic liver disease. Dig. Dis. Sci. 10 (1992), 239-248.
28. 28 Muggeo, M., A. Tiengo, D. Fedele: Altered control of growth hormone secretion in patients with cirrhosis of the liver. Arch. int. Med. 139 (1979), 1157-1160.
29. 29 Nathan, D. M., E. Schreiber, H. Fogel et al.: Preliminary studies of insulinotropic actions of glucagon-like peptide-1-(7-37) administration to diabetic and non-diabetic human subjects. Diabet. Care 15 (1992), 270.
30. 30 Naunyn, B.: Glykosurie und Diabetes durch experimentelle Insulte und Krankheiten der Leber. In: Nothnagel E. Handbuch Spez. Path. Ther. Band. 7, 1. Aufl. (Wien, A. Holder, Der Diabetes mellitus 1898) pp 38-49.
31. 31 Orskov, C.: Glucagon-like peptide-1, a new hormone of the entero-insulinar axis. Diabetologia 35 (1992), 701.
32. 32 Owen, O. E., F. A. Reichle, M. A. Mozzoli et al.: Hepatic, gut and renal substrate flux rates in patients with hepatic cirrhosis.J. clin. Invest. 68 (1981), 240-252.
33. 33 Petrides, A. S., C. A. Riely, L. C. Groop, R. A. DeFronzo: The glucose fatty-acid cycle does not explain the insulin resistance of cirrhosis. Gastroenterology 92 (1987), 1763.
34. 34 Petrides, A. S., R. A. DeFronzo: Glucose metabolism: A review with some perspectives for the future. Diab. metabol. Rev. 5 (1989), 691.
35. 35 Petrides, A. S., L. Groop, C. Riely, R. A. DeFronzo: Effect of hyperinsulinemia on glucose and lipid metabolism in cirrhosis. J. clin. Invest. 88 (1991), 561-570.
36. 36 Petrides, A. S., D. Schulze-Berge, C. Vogt, D. E. Matthews, G. Strohmeyer: Glucose resistance contributes to diabetes mellitus in cirrhosis. Hepatology 18 (1993), 284-291.
37. 37 Petrides, A. S., C. Vogt, D. Schulze-Berge, D. Matthews, G. Strohmeyer: Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 19 ( 1994), 616-627.
38. 38 Proietto, J., F. J. Dudley, P. Aitken, F. P. Alford: Hyperinsulinemia and insulin resistance of cirrhosis. Clin. Endocrinol.21 (1984a), 657-665.
39. 39 Randle, P. J., P. B. Garland, C. N. Hales: The glucose fatty acid cycle. Lancet 1(1963), 785-789.
40. 40 Riggio, O., M. Merli, A. Cantafora et al.: Total and individual free fatty acid concentrations in liver cirrhosis. Metabolism 33 (1984), 646-651.
41. 41 Romijn, J. A., E. Endert, H. P. Sauerwein: Glucose and fat metabolism during short term starvation in cirrhosis. Gastroenterology 100 (1991), 731-737.
42. 42 Selberg, O., W Burchert, J. Hoff et al.: Insulin resistance in liver cirrhosis. Positron-emission tomography scan analysis of skeletal muscle glucose metabolism. J. clin. Invest. 91 (1993), 1897-1902.
43. 43 Shmueli, E., M. Stewart, K. G. M. M. Alberti, C. O. Record: Growth hormone, IGF-I, and insulin resistance in cirrhosis. J. Hepatol. 18 (1993), 265.
44. 44 Shmueli, E., J. P. Miell, M. Stewart, K. G. M. M. Alberti, C. O. Record: High Insulin-like growth factor binding protein 1 levels in cirrhosis: link with insulin resistance. Hepatology 24 (1996), 127-133.
45. 45 Shankar, T. P., S. S. Solomon, W. C. Duckworth, T. Jerkins, R. S. Iyer, M. A. Bobal: Growth hormone and carbohydrate intolerance in cirrhosis. Hormon. metab. Res. 20 (1988), 597-583.
46. 46 Sherwin, R. S., M. Fisher, J. Bessoff: Hyperglucagonemia in cirrhosis. Gastroenterology 74 (1978), 124-1228.
47. 47 Sherwin, R. S., M. Fisher, R. Hendler: Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. New Engl. J. Med. 294 (1976), 455-461.
48. 48 Siegel, E. G., A. Seidenstücker, B. Gallwitz et al.: Insulin secretion defects in liver cirrhosis can be reversed by GLP-1 and its analogues. Studies in isolated rat islets. J. Endocrinol. (1999), accepted.
49. 49 Smith-Laing, G., H. Orskov, M. B. R. Gore, S. Sherlock: Hyperglucagonemia in cirrhosis. Diabetologia 19 (1980), 103-108.
50. 50 Tug, H., A. Wilmer, W. Vogel et al.: Serum levels of cytokines in chronic liver diseases. Gastroenterology 193 (1992), 264-274.
51. 51 Unger, R. H., S. Grundy: Hyperglycemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance. Diabetologia 85 (1985), 119-121.